Despite some encouraging top-line data from Sage Therapeutics Inc.’s phase III Mountain study of SAGE-217 on depressive symptoms in adults with major depressive disorder (MDD), the company, the market and analysts were taken aback at the trial’s failure to hit its primary endpoint.
Civetta Therapeutics LLC will take a $53 million series A to advance its platform and programs based on beta-propeller proteins that mediate protein-to-protein interactions. Those proteins can become involved in cancers, neurodegeneration and metabolic disorders, with oncology being the company’s initial focus.
Protagonist Therapeutics Inc. stock (NASDAQ:PTGX) nosedived 47% on Tuesday after the company released preliminary results from its phase II open-label study of PTG-300, an injectable hepcidin mimetic to treat patients with transfusion-dependent beta-thalassemia.
In its second large deal of the calendar year, Neurocrine Biosciences Inc. acquired the rights to Xenon Pharmaceutical Inc.’s selective sodium channel inhibitor for treating epileptic encephalopathy. Xenon receives $30 million up front, $20 million in equity and up to $1.7 billion in potential development, regulatory and commercial milestone payments.
Positive phase III data from the Advocate trial by Chemocentryx Inc. and Vifor Fresenius Medical Care Renal Pharma caused Chemocentryx’s stock (NASDAQ:CCXI) to dramatically rise 281% on Tuesday, clearing the way to an NDA filing for the star small-molecule attraction, avacopan, an oral, selective complement 5a receptor inhibitor.
La Jolla Pharmaceutical Co. discontinued its study LJ401-BT01 due to lack of efficacy and will reassess further development of LJPC-401 (synthetic human hepcidin) based on recent mixed clinical results.
The research challenge facing the scientific founders of newly launched Immunitas Therapeutics Inc. was getting human samples to deeply analyze in their quest to understand autoimmunity. While the research continued slowly, the science raced ahead.
Harpoon Therapeutics Inc. and Abbvie Inc. have cut their second deal in little more than two years as they embark upon an exclusive worldwide option and license transaction for HPN-217, Harpoon’s B-cell maturation antigen T-cell engagers targeting solid tumors and hematologic malignancies.
Even though November’s full moon had come and gone more than a week previous, Werewolf Therapeutics Inc. came out of the shadows Wednesday with a $56 million series A fundraiser to state its plans to develop immune-stimulatory therapeutics to trigger immune responses to cancer.
While Burt Adelman has been in Boston since 1991, it wasn’t until he joined Novo Ventures Inc. about four years ago that he realized there was often no way to tie the area’s drug development together into something resembling a cohesive whole.